Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Cingulate Inc. Warrants (CINGW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/12/2025: CINGW (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -96.9% | Avg. Invested days 26 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/12/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta -0.86 | 52 Weeks Range 0.01 - 0.18 | Updated Date 06/19/2025 |
52 Weeks Range 0.01 - 0.18 | Updated Date 06/19/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.73 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -114.14% | Return on Equity (TTM) -358.06% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 4237731 |
Shares Outstanding - | Shares Floating 4237731 | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
Cingulate Inc. Warrants
Company Overview
History and Background
Cingulate Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics for attention deficit hyperactivity disorder (ADHD). It focuses on its two lead product candidates, CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine). These warrants are rights to purchase the common stock under specific conditions.
Core Business Areas
- Pharmaceutical Development: Focuses on the research and development of therapies for ADHD.
Leadership and Structure
Information on Cingulate Inc.'s leadership and organizational structure is publicly available through its investor relations website and SEC filings.
Top Products and Market Share
Key Offerings
- CTx-1301: An oral, immediate-release/extended-release tablet formulation of dexmethylphenidate for ADHD. No current market share data. Competitors include generic and branded formulations of methylphenidate.
- CTx-1302: An oral, immediate-release/extended-release tablet formulation of dextroamphetamine for ADHD. No current market share data. Competitors include generic and branded formulations of amphetamine.
Market Dynamics
Industry Overview
The ADHD market is a growing market driven by increased diagnosis rates and awareness. It is characterized by a mix of generic and branded products.
Positioning
Cingulate aims to differentiate itself with novel formulations designed for improved efficacy and duration of action.
Total Addressable Market (TAM)
The ADHD market is estimated to be worth billions of dollars annually. Cingulate is positioned to capture a portion of this market with successful development and commercialization of its products.
Upturn SWOT Analysis
Strengths
- Novel drug formulations for ADHD
- Experienced management team
- Potential for improved efficacy and duration
Weaknesses
- Clinical stage company (no products on the market)
- Reliance on successful clinical trials
- Limited financial resources
Opportunities
- Growing ADHD market
- Potential for strategic partnerships
- Expanding product pipeline
Threats
- Regulatory hurdles
- Competition from established pharmaceutical companies
- Patent challenges
Competitors and Market Share
Key Competitors
- SHPG
- TEVA
- VRX
Competitive Landscape
Cingulate faces competition from established pharmaceutical companies with marketed ADHD products. Its success depends on demonstrating superior efficacy and safety.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is measured by progress in clinical trials and securing funding.
Future Projections: Future growth depends on successful clinical trials, regulatory approvals, and commercialization of its products.
Recent Initiatives: Recent initiatives focus on advancing clinical trials for CTx-1301 and CTx-1302.
Summary
Cingulate Inc. Warrants represent an investment in a high-risk, high-reward clinical-stage company. The company's success hinges on the positive outcomes of its clinical trials for CTx-1301 and CTx-1302. Key challenges include securing funding, navigating regulatory hurdles, and competing with established players in the ADHD market. While promising, the warrants carry significant risk due to the inherent uncertainties in pharmaceutical development. Successfully bringing drugs to market could drive considerable returns.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Cingulate Inc. Investor Relations
- SEC Filings
- Third-Party Market Research Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Investment decisions should be based on thorough research and consultation with a financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Cingulate Inc. Warrants
Exchange NASDAQ | Headquaters Kansas City, KS, United States | ||
IPO Launch date 2021-12-08 | Co-Founder, CEO & Chairman of the Board Dr. Shane J. Schaffer Pharm.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 13 | Website https://www.cingulate.com |
Full time employees 13 | Website https://www.cingulate.com | ||
Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company develops medications capable of once-daily dosing using its proprietary drug delivery platform technology, Precision Timed Release. Its drug candidates include CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials, as well as CTx-1302 (dextroamphetamine), which is in Phase 1/2 clinical pharmacology and Phase 3 clinical efficacy and safety trials for the treatment of ADHD in children, adolescents, and adults; and CTx-2103 (buspirone) that is in a formulation stage for the treatment of anxiety and related disorders. Cingulate Inc. was founded in 2012 and is headquartered in Kansas City, Kansas.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.